National Emerging Infectious Diseases Laboratories Operations

国家新发传染病实验室运营

• 批准号: 10226606
• 负责人: RONALD B CORLEY
• 金额: $ 1150万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10226606
• 关键词: Advanced Development; Animal Model; Animals; Area; Attention; Basic Science; Biology; Boston; Categories; Clinical Research; Collaborations; Communities; Comparative Study; Complement; Containment; Development; Diagnosis; Diagnostic; Diagnostic tests; Discipline; Emergency Situation; Emerging Communicable Diseases; Engineering; Environment; Environmental Health; Event; Faculty; Faculty Recruitment; Goals; Group Practice; Health; Human; Human Resources; Infectious Diseases Research; Information Technology; Institutes; International; Investigation; Laboratories; Medical; Medical center; Methodology; Mission; Modeling; Pathogenesis; Pathogenicity; Physiological; Process; Public Health; Public Health Schools; Reporting; Research; Research Personnel; Research Support; Safety; Science; Scientist; Secure; Security; Services; Strategic Planning; Teaching Hospitals; Therapeutic; Training; Training and Education; Translational Research; United States; Universities; Vaccines; Veterinary Pathology; biodefense; biosecurity; emerging pathogen; experience; flexibility; human disease; improved; innovation; insight; interest; medical schools; microbial; new technology; next generation; operation; pandemic disease; pathogen; pre-clinical research; prevent; programs; recruit; research and development; research facility; response; skills; tool; vaccine evaluation

Overall Abstract The National Biocontainment Laboratory (NBL) at Boston University (BU) is known as the National Emerging Infectious Diseases Laboratories (NEIDL). It is owned and operated by BU and is located on the Boston University Medical Campus (BUMC) adjacent to the BU School of Medicine, the Graduate Sciences program, the BU School of Public Health, and the affiliated teaching hospital, Boston Medical Center. The NEIDL's missions are: (1) To perform innovative basic, translational and clinical research on emerging infectious diseases in order to develop diagnostic tests, treatments and vaccines to promote the public's health; (2) To provide training in these areas of research and to support a national response in the event of a biodefense emergency; and (3) To establish a research facility with the highest attention to community and laboratory safety and security. In order to successfully achieve these missions, the NEIDL's goals are to: (1) Recruit and develop a cadre of investigators and research staff with expertise in the scientific disciplines required to investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents, including collaborations within the university, in the United States, and internationally; (2) Develop animal models for the comparative study of these pathogens, mimicking as closely as possible the human disease process, and build capacity for the creation and use of relevant animal models and innovative veterinary research support; (3) Perform translational, preclinical and clinical research in animals and humans; (4) Develop the methodologies needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents; (5) Train the next generation of research scientists and related support personnel in the requirements to perform maximum containment research in a safe and secure environment;( 6) Maintain the flexibility needed to support a national response in the event of a biodefense emergency; (7) Establish a "safety first" environment for the conduct of all activities in the Institute. Since opening for research at the BSL-4 and ABSL-4 levels in 2018, NEIDL has rapidly moved forward to recruit additional faculty whose skills and interests both expand and complement existing expertise, bring innovative new insights and methodology to expand our scientific capabilities, open up research on new pathogens. In order to advance vaccines and therapeutics, the NEIDL has expanded its Regulatory Compliance Group and practices to permit studies to be carried out under Well- Documented practices. The NEIDL focuses on and supports innovative science, led by our faculty investigators, and as a result we also continue to evolve our integrated research support services to provide support needed for BSL-4 research to better reflect and provide access to new technology and research approaches, in order to remain at the leading edge of science.

总括 摘要 波士顿大学的国家生物遏制实验室(NBL)被称为国家新兴实验室 传染病实验室(NEIDL)。它由BU拥有和运营，位于波士顿 大学医学院(BUMC)毗邻北大医学院，研究生科学计划， 波士顿大学公共卫生学院和附属教学医院波士顿医学中心。内德尔一家 任务是：(1)对新出现的传染病进行创新的基础、翻译和临床研究 发展诊断测试、治疗方法和疫苗，以促进公众健康； 在这些研究领域提供培训，并在发生生物防御事件时支持国家反应 紧急情况；及(3)建立最重视社区和实验室的研究设施 安全和安保。为了成功完成这些任务，Neidl的目标是：(1)招募和 培养一支拥有所需科学学科专业知识的调查人员和研究人员队伍 调查由A、B和C类病原体引起的新发传染病的发病机制，包括 大学内部、美国和国际上的合作；(2)为 对这些病原体进行比较研究，尽可能地模仿人类的疾病过程，并建立 创建和使用相关动物模型和创新兽医研究支持的能力；(3) 在动物和人类身上进行翻译、临床前和临床研究；(4)开发方法学 (5)推动这些药物的疫苗、治疗和诊断技术的开发和测试； 培训下一代研究科学家和相关支持人员，了解执行以下任务的要求 在安全可靠的环境中进行最大限度的遏制研究；(6)保持所需的灵活性，以 支持国家在发生生物防御紧急情况时做出反应；(7)建立“安全第一”的环境 负责研究所内所有活动的开展。自#年开放进行BSL-4和ABSL-4级别的研究以来 2018年，Neidl迅速招聘了更多的教师，他们的技能和兴趣既有扩展又有兴趣 补充现有专业知识，带来创新的见解和方法，以扩展我们的科学 能力，开启对新病原体的研究。为了推进疫苗和疗法，Neidl 已扩大其监管合规小组和做法，以允许在井下进行研究- 有记录的做法。Neidl专注于并支持由我们的教员领导的创新科学 研究人员，因此我们还继续发展我们的综合研究支持服务，以提供 BSL-4研究所需的支持，以更好地反映和提供获得新技术和研究的途径 方法，以保持在科学的前沿。